Enlivex Therapeutics Reports Positive Phase I Data for Allocetra™
Ticker: ENLV · Form: 6-K · Filed: Dec 3, 2024 · CIK: 1596812
Sentiment: bullish
Topics: clinical-trial-data, drug-development, biotech
Related Tickers: ENLV
TL;DR
Enlivex (ENLV) drops positive Phase I COVID-19 drug data, could be a catalyst.
AI Summary
On December 3, 2024, Enlivex Therapeutics Ltd. announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II trial for Allocetra™. The trial is evaluating Allocetra™ in patients with severe COVID-19. The company is organized under the laws of Israel and its principal executive offices are located in Nes Ziona.
Why It Matters
Positive trial data could advance Enlivex's lead drug candidate, Allocetra™, towards further clinical development and potential market approval for severe COVID-19.
Risk Assessment
Risk Level: medium — The data is from an early-stage Phase I trial, and further clinical trials are needed to confirm efficacy and safety.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Allocetra™ (drug) — Lead drug candidate
- December 3, 2024 (date) — Date of press release
- Phase I (clinical_trial_stage) — Stage of trial reporting data
- Phase I/II (clinical_trial_stage) — Overall trial designation
- COVID-19 (disease) — Condition being treated
- Israel (country) — Country of incorporation and operations
FAQ
What specific positive interim efficacy data was announced for Allocetra™ in the Phase I trial?
The filing states that positive interim efficacy data was announced, but does not provide specific details or metrics within the provided text.
What is the primary indication being investigated for Allocetra™ in this trial?
The trial is evaluating Allocetra™ in patients with severe COVID-19.
What is the current stage of the clinical trial for Allocetra™?
The trial is a randomized, multi-country Phase I/II trial, and the announcement pertains to interim data from the Phase I stage.
When was the press release announcing this data issued?
The press release was issued on December 3, 2024.
Under which country's laws is Enlivex Therapeutics Ltd. organized?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
Filing Stats: 225 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-12-03 08:32:02
Filing Documents
- ea022336301-6k_enlivex.htm (6-K) — 9KB
- ea022336301ex99-1_enlivex.htm (EX-99.1) — 24KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-104801.txt ( ) — 44KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: December 3, 2024 2